Compound ID | 1956
Synonym(s): XNW4107
Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])
| Details of activity: | DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound. In clinical development in fixed combination with imipenem/cilastatin |
| Institute where first reported: | Suzhou Sinovent Pharmaceuticals |
| Year first mentioned: | 2021 |
| Highest developmental phase: | Phase 3 |
| Development status: | Active (as of 2024) |
| Chemical structure(s): | |||||||||||||
|
|
||||||||||||
|
|
||||||||||||
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/158340749 |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/104838 |
| Guide to Pharmacology: | funobactam |
| Citation: | https://www.sciencedirect.com/science/article/pii/S2213716522001722 |